Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentYahoo Finance· July 26, 2026

AT&T Beat on Earnings, Announced a $10 Billion Buyback, and Still Trades at 8 Times Earnings With a 4.6% Yield.

View original at finance.yahoo.com
AT&T Beat on Earnings, Announced a $10 Billion Buyback, and Still Trades at 8 Times Earnings With a 4.6% Yield. The market has spent years treating AT&T (NYSE: T) as a bond that happens to trade on an exchange…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Data points we hold from this source

AT&T Inc. · stock price24.13 USD
AT&T Inc. · 52 week high29.79 USD
AT&T Inc. · pe ratio8 ratio
AT&T Inc. · fixed wireless customers added279000 customers
AT&T Inc. · adjusted ebitda margin39.1 percent
AT&T Inc. · planned shareholder returns total18 USD
AT&T Inc. · annual dividend total7.6 USD
AT&T Inc. · free cash flow4.7 USD
AT&T Inc. · fiber locations passed38.6 millions
AT&T Inc. · fiber customers added367000 customers
AT&T Inc. · diluted eps continuing ops0.66 USD_per_share
AT&T Inc. · internet customers added646000 customers
AT&T Inc. · annual dividend per share1.11 USD
AT&T Inc. · eps0.65 USD_per_share
AT&T Inc. · shares outstanding6.9 billions
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com